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Both B and T lymphocytes have signature traits that set them apart
from other cell types. They actively and repeatedly rearrange their DNA
in order to produce a unique and functional antigen receptor, they have
potential for massive clonal expansion upon encountering antigen via this
receptor or its precursor, and they have the capacity to be extremely long
lived as ‘memory’ cells. All three of these traits are fundamental to their abil-
ity to function as the adaptive immune response to infectious agents, but
concurrently render these cells vulnerable to transformation. Thus, it is clas-
sically considered that lymphomas arise at a relatively late stage in a
lymphocyte’s development during the process of modifying diversity
within antigen receptors, and when the cell is capable of responding to
stimulus via its receptor. Attempts to understand the aetiology of lymphoma
have reinforced this notion, as the most notable advances to date have
shown chronic stimulation of the antigen receptor by infectious agents
or self-antigens to be key drivers of these diseases. Despite this, there
is still uncertainty about the cell of origin in some lymphomas, and increas-
ing evidence that a subset arises in a more immature cell. Specifically, a
recent study indicates that T-cell lymphoma, in particular nucleophosmin-
anaplastic lymphoma kinase-driven anaplastic large cell lymphoma, may
originate in T-cell progenitors in the thymus.1. Lymphoma as a cancer of the immune system
Lymphomas belong to a family of tumours that affect haematopoietic and lym-
phoid tissues, which includes leukaemia. Broadly, lymphoma is distinguished
from leukaemia in its clinical presentation, where lymphoma predominately
involves lymph nodes, and leukaemia the blood and bone marrow, and by
the fact that lymphomas arise from cells that reside in the lymphatic system
rather than in the bone marrow. However, in the context of the cell of origin
this is perhaps a rather nebulous distinction, and there is evidence that chronic
lymphocytic leukaemia (CLL) may emerge in differentiated/mature lympho-
cytes in the periphery. For example, it has been suggested that CLL may
arise in marginal-zone B cells [1], regulatory B cells [2] or memory B cells [3],
with B-cell receptor (BCR) signalling representing a key promoting factor [1].
Similarly, in adult T-cell leukaemia/lymphoma (ATLL), a mature T-cell neo-
plasm, the cell of origin is a post-thymic lymphocyte infected by the human
T-cell lymphotropic virus (HTLV-1). Notably, it presents as a leukaemia in
more than two-thirds of patients, and as a lymphoma in the remainder [4].
At the other extreme, B/T-lymphoblastic leukaemia/lymphoma is a neoplasm
of immature B cells or T cells, arising from precursor B cells in the bone marrow
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Figure 1. B-cell development and the origins of B-cell lymphoma. B-cell development commences in the bone marrow whereby committed B cells rearrange the
immunoglobulin (Ig) genes to generate a B-cell receptor. On entering the periphery, B cells congregate in lymphoid tissue wherein antigen-dependent B-cell
development takes place. Naive B cells on encountering antigen become activated and generate germinal centres in which the processes of somatic hypermutation
(SHM) and class switch recombination (CSR) take place in the dark and light zones, respectively. Studies of the status of the Ig genetic regions within lymphoma
cells can align their origin in either pre- or post-germinal centre B cells. For example, the majority of mantle cell lymphoma (MCL) do not display mutations within
V-region genes suggesting they have not passed through the germinal centre and are therefore presumed naive. The origin of lymphomas is also assumed from their
growth pattern and cell surface expression of proteins indicative of stages of B-cell development. MALT, mucosal-associated lymphoid tissue lymphoma; MZL, mar-
ginal-zone lymphoma; DC, dendritic cell; DLBCL, diffuse large B-cell lymphoma; CLP, common lymphoid progenitor; HSC, haemopoietic stem cell; GC, germinal centre
B cell; FDC, follicular dendritic cell; Tfh, follicular helper T cell; FL, follicular lymphoma; BL, Burkitts lymphoma. Acronyms in red denote the presumed cell of origin
of the indicated lymphoma sub-type.
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considered as two diseases, acute lymphoblastic leukaemia
(ALL) and lymphoblastic lymphoma (LBL), based on the
presence of more or less than 25% bone marrow blasts,
despite the fact that they share many morphological and
immunophenotypic features [6]. Thus, it is quite likely that
in terms of the mechanisms of tumourigenesis and the cell
types involved, the aetiology of lymphoma and leukaemia
overlap. However, for the sake of clarity and brevity, this
review is only considering the origin of cancer in lympho-
cytes that leads to a disease that has been classified
as lymphoma.
Considering lymphomas specifically, the progression
of the disease has yet to be completely understood. At
some point along the journey of a lymphocyte from its
haematopoietic stem cell origin to its fully differentia-
ted mature destination, a build-up of genetic mutations
can lead to the transformation and subsequent clonal
expansion of this lymphocyte, resulting in the formation of
lymphoma. A key initiating genetic event is in some cases
a chromosomal translocation, usually resulting from a
balanced reciprocal recombination event. Illustrating this,
chromosomal translocations are present in up to 90% of
non-Hodgkin lymphoma (NHL), the majority lymphoma cat-
egory [7]. Lymphomas, like most cancer types, are extremely
diverse, and a number of different entities have been
described, distinguished from each other by morphologic,
immunophenotypic and genetic features [8]. Attempts to
understand lymphoma aetiology as a whole has been challen-
ging in the face of such apparent complexity. It is likely that
in order to gain a deeper understanding of this disease’s
origins and development, it is better to regard it as a mixture
of different disease entities with potentially varying aetiolo-
gies. This review discusses the cellular origin of lymphoma,specifically with regard to the state at which differentiation
arrest occurs in order to give rise to the plethora of NHL
sub-types observed.2. Development of lymphocytes
Defining what makes a lymphocyte immature or mature is
critical if we are to differentiate the origin of lymphomas
on that basis. In simple terms, when a lymphocyte is no
longer capable of giving rise to more than one haematopoie-
tic lineage, and has assembled all the necessary structures to
perform its function, it has reached maturity. For B cells,
their period of immaturity spans their life in the bone
marrow, broadly defined by the lack of cell surface immu-
noglobulin but with the presence of the cell surface
protein CD19 (figure 1). The earliest B-cell precursors, pre-
pro-B cells, can still give rise to T cells, natural killer (NK)
cells and dendritic cells (DCs), but as they reach the
pro-B-cell stage they lose multi-potentiality and begin
assembling immunoglobulin, maturing further into the
pre-B-cell and immature B-cell stages (accompanied by the
expression of surface IgM). B cells complete their maturation
in secondary lymphoid organs such as the spleen [9]. For T
cells, their development begins in the thymus as their ear-
liest precursor, the pro-T cell (which is CD34þCD1a2 in
humans, CD42 CD82CD252CD44þ (DN1) in mice), when
they still have the potential to differentiate into the B-cell,
myeloid, NK and DC lineages (figure 2 and reviewed in
[10]). The precursor thymocyte is only committed to the
T-cell lineage following rearrangement of T-cell receptor
(TCR) d, g and then b regions at the early double positive
(DP) stage (CD32CD4þCD8þ in humans, CD42CD82-
CD25þCD442 (DN3) in mice) [11]. Cells with productive
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Figure 2. Human T-cell development and the origins of T-cell lymphoma. T-cell development occurs in the thymus wherein early thymic progenitors from the bone
marrow pass through the double negative (DN) stages rearranging the T-cell receptor genes in an ordered process to enable bypass of the beta selection checkpoint
or differentiation into gd T cells. Following both positive and negative selection, surviving T cells differentiate into either innate, regulatory (Treg), natural killer/T
(NKT), cytotoxic or helper (Th) T-cell subsets. In an antigen-dependent process, these cells can further differentiate into distinct T-cell subsets or memory cells.
T-lymphoblastic lymphoma (TLBL) arises from the immature thymic T cells whereas peripheral T-cell lymphoma (PTCL) has origins in mature, terminally differ-
entiated T cells. By contrast, the origins of anaplastic large-cell lymphoma (ALCL), a peripheral T-cell disease, are controversial. Ag, antigen; TCL, T cell
lymphoma; NKTCL, natural killer T-cell lymphoma. Dashed arrows represent less well-established differentiation pathways.
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DP cells, and complete their maturation in the thymus,
becoming either CD4þ or CD8þ single positive (SP) cells
following MHC restriction, before eventually migrating to
the periphery [12] (figure 2).
Once they have reached maturity B lymphocytes undergo a
series of processes that enable diversity in antigen recognition
(somatic hypermutation and class switch recombination) within
germinal centres of lymphoid follicles in secondary lymphoid
organs (figure 1). Naive B cells present in the mantle zones of fol-
licles on interaction with antigen presenting helper T cells are
stimulated to move into the germinal centre whereupon they
undergo the processes of somatic hypermutation and class
switch recombination to emerge as activated post-germinal
centre B cells [13]. Those B cells that express an antigen receptor
with increased affinity for antigen (usually presented to the cells
on the surface of follicular DCs) are then selected, the remaining
cells undergoing apoptosis [14]. Mature B cells then exit into the
periphery as antibody-producing plasma cells or long-lived
memory cells [15].3. Mechanisms of lymphomagenesis in
‘mature’ lymphocytes
3.1. Lymphoid cell developmental processes contribute
to lymphomagenesis
Key to lymphomagenesis in mature lymphocytes is that most
of the developmental processes described above have the
potential to introduce oncogenic mutations. The formation
of the antigen receptor in B and T cells involves recombin-
ation activating gene (RAG) 1/2 endonucleases initiating
V(D)J recombination, leading to immunoglobulin or T cell
receptor (TCR) assembly, respectively [16]. Further, V(D)J
rearrangement may occur in mature B cells (receptor revision)
[14] and may lead to translocation of the Ig loci to oncogenes
including c-myc [15]. Class switch recombination, where the
constant regions of the B cell receptor are changed, allows the
effector function of the antibody to be altered [17]. Thus,
when breakpoints that lead to oncogenic translocations are
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genes, it is probably a result of mistaken class switch recom-
bination. This is the case for several translocations, including
MYC in Burkitt lymphoma [18] and BCL6 in diffuse-large-B
cell lymphoma [19].
Somatic hypermutation in B cells generates ‘mutations’
within the immunoglobulin variable regions in a process
largely mediated by activation induced cytidine deaminase
(AID). This occurs during the B cell response to T-cell-
dependent antigens, allowing B cells to be selected on the
basis of improved affinity for the antigen [20]. However,
this process can be a cause of malignancy, directly or
indirectly. Directly, because it is capable of causing deletions
or insertions that can lead to oncogenic translocations, such
as MYC translocations in Burkitt lymphoma [21]. Indirectly,
as by changing the affinity for antigen, somatic hypermuta-
tion may allow a previously ‘normal’ B cell to make a
hyperactive response that could generate a malignancy as
discussed below [22].
The causes of chromosomal translocations and other
mutations in T cell lymphoma are less well understood
and few have been described. The most well known is the
anaplastic large-cell lymphoma (ALCL)-associated nucleo-
phosmin-anaplastic lymphoma kinase (NPM-ALK), the
consequence of a t(2;5)(p23;q35) event described further
below and for which the responsible mechanism remains
to be determined [23]. As such, data for mechanisms of
mature T-cell lymphomagenesis are lacking in comparison
with B-cell lymphomas, largely due to the relative scarcity
of known driver mutations through which to investigate
these diseases, their heterogeneity and their rarity. As such,
some of the evidence for T-cell lymphomas initiating in
mature T cells comes from serendipitous findings in mouse
models. For example, deletion of the SWI/SNF-related regu-
lator of gene expression SNF5 in mice leads to rapid onset of
mature peripheral T-cell lymphoma (PTCL) [24]. In a model
where expression of Snf5 was deleted in mature T cells but
not at earlier stages of thymic development, it was shown
that cells with a CD44hiCD122loCD8þ memory-like pheno-
type accumulated, with the mice eventually developing
CD8þ mature PTCL in the spleen, liver and lymph nodes
[25]. However, snf5 deletion has not been reported in
human PTCL (the region in which snf5 resides is deleted in
50% of prolymphocytic leukaemia [26]). However, these
data do indicate that memory cells might be the source of
T-cell lymphomagenesis, cells that inherently have the ability
to self-renew and are long-lived enabling the acquisition of
tumour-promoting mutations. Perhaps more relevant to
human PTCL is the oncogenic driver, interleukin-2 inducible
T-cell kinase-spleen tyrosine kinase (Itk-Syk) fusion protein
which has been associated with a small number of cases of
follicular-type PTCL and AITL [27,28]. Expression of Itk-
Syk via CD4 promoter-driven Cre in transgenic mice leads
to peripheral CD4 and/or CD8 SP T-cell lymphoma in mice
with tumour cells having an activated T-cell phenotype
(CD62loCD44hi; also indicative of an effector memory T
cell) [29]. Likewise, expression of lin28b, in this case from
the haemopoeitic-ubiquitous vav promoter, leads to a
PTCL-like disease in mice, although links to human disease
are tenuous, with Lin28b reported as being overexpressed
by on average 7.5-fold in PTCL, NOS (n ¼ 50) [30]. In this
latter case, tumour cells resemble follicular T cells, suggesting
an origin in this mature cellular compartment.3.2. Chronic antigenic stimulus and lymphomagenesis
3.2.1. Bacteria and lymphoma
As the interaction of antigen with its antigen receptor on
a lymphocyte leads to massive proliferation, it has long
been supposed that exposure (perhaps chronic) to infection
is an important factor in the formation of lymphoid cancers,
and this idea has been strengthened further by recent
studies of follicular lymphoma (FL). FL cells express Ig unu-
sually marked by the presence of glycan chains terminating
in mannose (as a result of somatic hypermutation-induced
mutations of the Ig) which recognize lectin on presenting
cells in the germinal centre (reviewed in [22]). Furthermore,
the Igs of the lymphoma cells recognize lectins from oppor-
tunistic pathogens such as Pseudomonas aeroginosa and
Burkholderia cenocepacia, suggesting a role for bacterial infec-
tion in the pathogenesis of this disease [31]. The association
of bacterial infection with lymphomagenesis is not a new
concept as the relationship of the bacterial species Helicobacter
pylori with mucosal-associated lymphoid tissue (MALT)
lymphoma is well documented, although the mechanism
in this scenario is not a direct interaction as described
below [32].
MALT lymphoma is a B-cell lymphoma that is associa-
ted with bacterial infection and auto-antigen stimulation.
MALT lymphomas are derived from marginal-zone B cells
in the Peyer’s patch, which they still highly resemble. These
cancerous cells proliferate and invade the epithelium, to
form lymphoepithelial lesions (LEL). MALT lymphomas
can remain localized or widely disseminate, and can also
transform into diffuse large B cell lymphoma [33]. There is
much evidence that gastric lymphoma arises from H. pylori
associated acquired MALT in the gastric mucosa (where
MALT is usually not found), one example being an associ-
ation between H. pylori infection and the development of
gastric lymphoma in a case controlled study [34]. Later exper-
iments showed that H. pylori specific T cells are present in the
tumour, and that they promote the growth of the B-cell
tumour cells by CD40-mediated signalling [35]. Hence, the
accepted view is that H. pylori induces accumulation of
MALT, and then promotes chronic inflammation by activat-
ing a T cell response, which in turn causes DNA damage
that eventually leads to the emergence of B cell neoplasia.
On top of this, the B-cell lymphoma cells continue to be
stimulated by auto-antigens directly, and by contact with
H. pylori specific T cells. Indeed, antibiotic therapy in some
cases leads to disease eradication [36].3.2.2. Viral mechanisms
As well as a link with bacterial infection, there is also a strong
association between viral infection and lymphoma, including
human T-cell lymphotropic virus-1 (HTLV-1), hepatitis C
virus (HCV) and Epstein–Barr virus (EBV). HCV is the excep-
tion in that it is not thought to be a pure ‘oncogenic’ virus, but
rather that it induces lymphoma by indirect means. Specifi-
cally, it is proposed that the E2 protein of HCV may cause
chronic antigen-driven responses in B cells, leading to lym-
phomagenesis [37]. EBV and, to a lesser extent, HTLV-1 are
oncogenic viruses in the traditional sense, though both gener-
ally also rely on normal mechanisms of mature lymphocyte
proliferation to induce lymphoma. EBV is a ubiquitous virus
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population [38]. In certain geographical areas, such as Africa,
where it is associated with Burkitt lymphoma, it is a major
cause of disease, although it usually requires some form of
immunosuppression in the individual, in particular due to
other infections such as malaria, in order to drive proliferation
of B cells [39]. However, in this latter case, tonic rather than
active BCR signalling is considered the driver of lymphoma-
genesis whereby the PI-3 kinase pathway is triggered rather
than the multitude of pathways including NFkB that are seen
in active signalling [40]. Indeed, high rates of lymphoma
have been observed in individuals that exhibit systemic
immune suppression, whether that is due to autoimmune
disease, organ transplantation or primary/acquired immuno-
deficiency, including HIV infection [41]. As immunodeficient
individuals cannot eliminate infections effectively, yet retain
B and T cells that can be activated, they are particularly
prone to chronic antigenic stimulation of their B and T cells,
which then promotes lymphomagenesis [42].
Of particular note are the lymphomas that arise in the con-
text of autoimmune disorders, including Sjogren’s syndrome
(SS). SS is a rheumatic autoimmune disease characterized by
lymphocytic infiltration and destruction of salivary and lacri-
mal glands [43]. The initiating factor may be viral: herpes
virus 6, cytomegalovirus and EBV among others have been
implicated [44], with persistent chronic stimulation being
maintained by auto-antigens such as Ro/SSA and/or La/
SSB. This drives the proliferation of specific B and T lympho-
cytes, increasing the likelihood of their transformation [45].
Thus, the major complication of this syndrome is lymphoma
[46],with approximately 5%of SS patients developing lympho-
cyte malignancy, in particular MALT lymphoma [47]. Despite
the fact that the development of B-cell lymphoma is more
frequent, there are T-cell malignancies associated with this
disease, with the most common sub-type being angioimmuno-
blastic T-cell lymphoma [48]. The number of different
malignancies associated with SS suggest there is more than
one ‘cell of origin’, but there is evidence that some of the B-cell
lymphomas may initiate in CD27þ memory B cells attracted
preferentially into inflamed salivary glands [49]. Other auto-
immune disorders also increase the risk of developing
lymphoma, including coeliac disease and dermatitis herpeti-
formis, which are both disorders triggered by gliadin. Coeliac
disease in particular has been linked to the uncommon
entropathy-type T-cell lymphoma of the small intestine [50].
3.2.3. Self-antigen stimulation
As alluded to above, the source of the antigen is not
necessarily derived from an external pathogen as it has also
been shown to derive from self, whereby chronic self-
antigen-induced signalling through the B-cell receptor
(BCR) is implicated in lymphomagenesis. For example, in
activated B-cell (ABC) DLBCL, chronic active BCR signalling
is considered essential for the survival of these tumour cells
and the mediators of this have been shown to range
from self-antigens in apoptotic debris to self-glycoproteins
[51,52]. In evidence, ABC DLBCL cell lines have prominent
BCR clusters, characteristic of normal B cells that have been
exposed to antigen [51]. Together, these data suggest a
continual requirement for proximal BCR signalling in some
lymphomas whether that be induced by an invading
pathogen or self-antigen.3.2.4. Signalling through the T-cell receptor and
lymphomagenesis
A role for signalling through the TCR and/or activation of
signalling proteins proximal to this receptor has also been
implicated in the pathogenesis of PTCL. For example, Itk-
Syk and NPM-ALK fusion proteins have both been shown
to mimic proximal TCR-induced signalling, in the former
case by associating with lipid rafts via its pleckstrin hom-
ology (PH) domain and in the latter by indirect activation
of AP1 and NFAT transcription factors [29,53–55]. In fact,
Itk-Syk expression in vivo was shown to be a strong mimic
of TCR signalling to the extent that it induced negative selec-
tion in the thymi of these mice [29]. Furthermore, activating
mutations of the CD28 co-stimulatory receptor of T cells
have been reported in a few cases of AITL and PTCL, NOS
[56]. Whether exogenous antigen signalling through the
TCR is also a driver for T-cell lymphomagenesis remains to
be proven, but the fact that many human PTCL express
gene signatures associated with activated T cells lends
some support [57,58]. Indirect evidence is provided by the
vav-Lin28b model in which expression of Lin28b led to a pro-
inflammatory environment whereby tumour cells expressed
NFkB and tumours contained many pro-inflammatory cyto-
kines [30] and the association of ALCL with insect bites and
breast implants [59–61]. In this vein, cutaneous T-cell lympho-
mas (CTCL) have long been associatedwith antigenic stimulus,
most recently as a consequence of the bacterial product Staphy-
lococcus enterotoxinA, albeit by indirectmeans [62]. This latter
example alludes to a role for an inflammatory environment
driving cellular proliferation which may enable the acquisition
of further tumour-promoting mutations. This mechanismmay
account for many further mutations that have been described
for PTCL in genes normally activated downstream of the anti-
gen receptor/in response to a pro-inflammatory environment
including for example STAT proteins [63,64].
In summary, the causes of the tumour-inducing chronic anti-
genic stimulation are varied, and lymphomagenesis initiated in
mature lymphocytes often involves other mechanisms such as
direct integration of oncogenic viral DNA, immunosuppression,
mutation-inducing developmental processes (e.g. SHM and
CSR) as well as exposure to environmental mutagens and
undoubtedly others yet to be determined.4. Mechanisms of lymphomagenesis in
‘immature’ lymphocytes
Compared with the wealth of evidence that lymphoma
emerges from late stage lymphocytes, there has been to date
less evidence that lymphomas begin from the opposite end
of the developmental pathway. In part, this is due to the ten-
dency of malignancies of progenitor B or T cells to produce
lymphocytic leukaemia rather than lymphomas, with the
major exception being LBL. LBL accounts for approximately
2% of all lymphomas, with the B-cell fraction accounting for
less than 10% of those cases (the remainder being of immature
T-cell lineage) [6]. Considering B-LBL specifically, the precur-
sor origin of this disease is distinguished from mature B-cell
neoplasms by the expression of markers of pro- or pre-B cells
such as CD19 and terminal deoxytransferase (TdT), and by
the absence of surface immunoglobulin [5].
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B cell can give rise to a malignancy. In one study, bone marrow
B-cell progenitors that were isolated and infected with Myc-
encoding retrovirus gave rise to B-cell lymphomas when
reinjected into recipient mice if p53 was also inactivated in
these cells [65]. The tumours resembled late pro-B/small
pre-B cells and had not formed clonal rearrangements of
the B-cell receptor. This suggests that loss of p53 and overex-
pression of myc is sufficient to cause lymphoma originating
in early B-cell progenitors [65]. A more recent, related study
also showed that B-cell progenitors may be more susceptible
to c-Myc-induced lymphomagenesis than theirmature counter-
parts. In this case, the cooperating mutation was the loss of
Msh2, a key element of the DNAmismatch repair pathway [66].
The immunophenotype of T-LBL often matches early
stages of T cell development in the thymus, with expression
of proteins such as CD2, CD34 and CD1a in the absence
of CD4 and CD8 [6]. It therefore follows that lymphomas
resembling immature T cells originate in their immature
thymic-resident counterparts whereby differentiation to a
mature T-cell phenotype is inhibited. For example, con-
ditional deletion of Pten in the thymus of mice causes
peripheral lymphomas, yet the tumour cells still resemble
immature thymic populations [67]. Therefore, T-LBL is con-
sidered to arise from immature lymphocytes and PTCL
from mature circulating lymphocytes. Yet, given the plasticity
of the haemopoietic system, one cannot rule out a thymic
origin for peripheral disease if T-cell development is
unaffected or even promoted by the driving oncogenic event.5. An immature origin for a mature T-cell
lymphoma?
As alluded to above, if tumour cells resembling immature thy-
mocytes can present as a peripheral disease, can tumour cells
representative of peripheral T cells also originate in thymic pre-
cursors but retain the ability to differentiate? This is probably
dependent on the driving tumour-promoting event and sub-
sequent contributory mutations, and whether they are able to
drive and/or be permissive of a differentiation programme,
while paradoxically retaining a stem cell programme or at a
later point re-acquiring this ability (perhaps, as a consequence
of differentiation into memory cells as indicated above or
through activation via mutation of a stemness gene signature).
In support, at least inmice, mature T cells appear to be resistant
to transformation byoncogenes such as LMO2, TCL1 orDTrkA
suggesting their expressionmust be targeted tomemory T cells
or other cells that already possess the ability to self-renew such
as progenitor populations [68]. The challenge of identifying the
cell of origin of a well characterized PTCL, ALCL, has led to
discoveries that suggest this disease is indeed seeded in imma-
ture thymocytes and that these incipient tumour cells develop
into a malignancy with a mature ‘activated-T-cell’ phenotype
in at least a subset of cases.
5.1. Anaplastic large-cell lymphoma and attempts to
model it in vivo
ALCL has an unusual presentation, often lacking in T cell-
specific cell surface proteins, yet with features indicative of
an activated mature T cell, making the natural progressionof the disease difficult to discern. The first defining features of
ALCL were discovered in the mid-1980s, when a series of dif-
fuse large-cell lymphomas were shown to strongly express
CD30, suggesting an activated lymphoid cell of origin [69].
This designation was further restricted to a T- or null-cell
phenotype, due to the expression of T-cell-specific cell surface
proteins such as CD4 and production of cytotoxic T-cell
proteins like perforin [70], together with clonal TCR
rearrangements [8], or in the latter case in the apparent
absence of any lineage defining markers. Regardless, the
presence of clonal TCR rearrangements in greater than 90%
of all cases assigns a T-cell origin to this disease [70]. The dis-
parities observed in cell surface marker expression profile
have provided some controversy towards identifying the
cell of origin for this disease; in some cases, CD25 is
expressed in combination with CD4 indicating a regulatory
T cell [71], whereas CD4 expression indicates a helper T cell
and CD8 and/or perforin a cytotoxic cell, although expression
of cytotoxic proteins has been linked toNPM-ALKactivity [72].
Yet in some cases CD4 and perforin are expressed, and
therefore it is not clear at which stage of T-cell development
this cancer arose and which physiological processes may or
may not contribute to the ensuing phenotype. Indeed, a
gene expression profiling study of three distinct entities of
ALCL, systemic ALKþ, systemic ALK2 and cutaneous
ALK2 could not assign the disease to CD4þ, CD8þ or
CD30þ T-cell origin [73].
What is clear is that a largemajority of ALCL are associated
with a specific chromosomal translocation, the t(2;5)(p23;q35),
whichwas described in the early 1980s andwas later identified
to be the fusion of a kinase gene, ALK, to a nucleolar protein
gene, Nucleophosmin 1 (NPM) [23]. The translocation break-
point gene product is the NPM-ALK fusion gene, which is
oncogenic due to key structural features. The 50 end of the
fusion, NPM, has an oligomerization domain that causes the
NPM-ALK fusion to form homodimers allowing the 30 end of
the fusion, the ALK kinase, to transphosphorylate becoming
constitutively activated [74]. However, it should be noted
that NPM-ALK transcripts are detected in cells of healthy indi-
viduals with a relatively high frequency, suggesting the fusion
product alone is insufficient to induce ALCL [75].
There have been several efforts to model NPM-ALK
driven ALCL in vivo, with the goal in part to define the cell
of origin of the disease. The first attempts involved retroviral
transduction of bone marrow ex vivo with NPM-ALK and
then injecting the cells into irradiated mice, which produced
immunoblast-like B cell lymphomas in peripheral nodes [76].
While this was the first confirmation that NPM-ALK has the
ability to transform lymphocytes as a consequence of its con-
stitutively active tyrosine kinase, it also suggests that it
cannot drive a T-cell developmental pathway, although the
bone marrow culture conditions employed in this study do
favour B-cell development [76]. Subsequently, a number of
models were designed to regulate NPM-ALK expression
with promoters that are specific to particular haemopoietic
lineages [77]. For example, the Vav promoter is known to
drive expression in all lineages of the haemopoietic system
including early progenitors [78], whereas the Lck proximal
[79] and CD2 promoters [80] drive expression from early
stages of T-cell development (DN2 and DN3, respectively).
In an effort to effectively ‘screen’ the haematopoietic com-
partment for the preferential target of NPM-ALK activity,
Turner et al. expressed NPM-ALK from the Vav promoter
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mice mainly developed plasmacytomas, suggesting that per-
haps NPM-ALK is more potent when expressed in B cells or
that, as expected and observed, B cells are more prone
to transformation than T cells (B-cell lymphoma is far more
prominent than T-cell lymphoma in humans). However,
NPM-ALK-induced B-cell lymphoma does exist, although
extremely rare [82]. These data suggest together that for
mice to develop a T-cell lymphoma, targeted expression of
NPM-ALK to thymocytes and/or mature T cells is required.
However, this has also led to mixed results, with CD2 pro-
moter-driven NPM-ALK transgenic mice also producing
lymphomas that appear to be of a B-cell phenotype [83],
and the CD4 promoter used in the same context leading in
some cases to plasmacytomas [84], suggesting that either
the promoters are ‘leaky’ in the transgenic setting or NPM-
ALK can alter cell-lineage differentiation. Of course, when
generating transgenic lines, one also has to consider the
effects of site of integration of the transgene in this regard.
Indeed, the CD4/NPM-ALK approach also gave rise to two
other transgenic lines, one that produced plasmacytomas or
thymic tumours, but another that exclusively develops
thymic T-cell lymphomas [84]; the reasons for these disparate
phenotypes from the same round of microinjection are not
immediately apparent and might reflect previously discussed
concepts. In a complementary approach, Lck promoter-
driven NPM-ALK gave rise again to immature thymic
T-cell tumours, but the disease was so aggressive the line
was not able to be maintained [85]. Regardless, in no cases
has a PTCL presented in mice expressing NPM-ALK in a
transgenic context even though the CD4 promoter also
drives expression in mature T cells (the CD4 promoter con-
struct used to generate these mice lacks silencing elements
that would normally supress expression in early thymocytes
[86]). The consequences of driving NPM-ALK expression
exclusively in mature T cells are yet to be explored, largely
due to the current lack of any peripheral T-cell-specific
promoters for use in the transgenic context (reviewed in [87]).5.2. Evidence for anaplastic large cell lymphoma arising
in progenitor T cells in the thymus
The difficulties in reproducing an ALCL-like disease in mice
suggests that the oncogenic activity of NPM-ALK needs to be
targeted to a specific stage of T-cell development, perhaps
with one or more cooperating mechanisms. The resemblance
of ALCL to an activated mature T cell, due to the expression
of activated T-cell proteins such as CD30, granzyme B and per-
forin [88], has led most work to concentrate on mature subsets
as the ‘normal counterpart’ of ALCL, with suggestions includ-
ing IL-17-producing Th17 cells [89] or Foxp3 expressing T regs
[71,90]. It has also been shown thatmature humanCD4þ T cells
can be transformed by NPM-ALK in vitro [91]. An alternative
hypothesis is that thymic expression of NPM-ALK is reflective
of the human scenario but that other mechanism(s) contribute
to the pathogenesis of the disease to eventually give rise to a
peripheral lymphoma of apparent mature T cells. In support
of this, transcripts for NPM-ALK have been detected in haema-
topoietic stem cell-rich cord blood of 1.95% of healthy
newborns (n ¼ 103) [92]. While this statistic does not concur
with the low ALCL incidence of 1.2 million of the general
population, it does suggest an early event is possible; indeed,the NPM promoter that drives expression of NPM-ALK in
humans is active throughout thymic development [86]. Fur-
thermore, ALCL, ALKþ is largely diagnosed in children and
young adults (when the thymus is at its largest) and an
in utero origin for the translocation is in fitting with previous
studies of childhood leukaemia [93,94]. It therefore follows
that if NPM-ALK expression in cord blood is the source of inci-
pient tumour cells, then why is NPM-ALK expression largely
restricted to PTCL in humans? The obvious answer to this is
that secondary, perhaps peripheral events are important to
disease pathogenesis although mediastinal involvement is
observed in up to 50%ofALCL cases [95]. However, in support
of a thymic presence of incipient tumour cells, our own studies
turned towards human ALCL tumours and investigations for
any clues that would point towards aberrant thymic events
that might be induced by, and be a marker of the presence
and expression of NPM-ALK in patient thymi [86]. Given
that rearrangement of TCR genes is a tightly controlled and
regulated process occurring in a temporal, step-wise manner
and pertubations to this could indicate obstructive or at least
subverted processes in the thymus. Indeed, our studies of
CD4/NPM-ALK transgenic mice show a delay at the DN3
stage of thymic development, the point in thymic development
at which b-selection is occurring (figure 2); it is therefore likely
that if NPM-ALK is subverting processes in the human
thymus, it would be at this stage when TCRb chain rearrange-
ment is taking place. This led us to assess by PCR and array
CGH the clonality of TCR rearrangements of human ALKþ
ALCL malignancies and expression of any consequent TCR.
Around two-thirds of the samples tested had undergone
major in-frame clonal TCRa rearrangement in the absence of
a comparable major TCRb clonal rearrangement [86]. There
were minor clonal TCRb rearrangements, thought to either
be indicative of infiltrating inflammatory T cells or ongoing
rearrangements within sub-clones of the major tumour cell
clone. This is a TCR profile that is not consistent with normal
thymocyte development but is consistent with observations
made by ourselves and others that ALCL very rarely express
the TCRb protein by immunohistochemistry [86,96] and, more
specifically, with our observation that NPM-ALK can replace
the TCRb signalling cascade in mice (CD4/NPM-ALK/
RAG2/2 mice produce thymic lymphomas that appear to be
mature, post TCR-rearrangement thymocytes) [53,97]. In further
evidence of a thymic origin, studies of tumour-propagating cells
in ALCL cell lines and patient tumours show an early thymic
progenitor genetic signature [98]. Whether the thymic environ-
ment plays an essential role in tumorigenesis or if the aberrant
thymic events detected are purely consequential of NPM-
ALK-induced Notch 1 remains to be determined [86]. This
then leaves the question of how primitive thymic T cells expres-
sing NPM-ALK become mature T-cell lymphomas, especially
given that expression of NPM-ALK in the thymi of mice fails
to produce this disease phenotype [84].5.3. Thymic nucleophosmin-anaplastic lymphoma
kinase expression in the presence of a transgenic
clonal T-cell receptor gives rise to peripheral T-cell
lymphoma in mice
If ALCL originates in the thymus, then the cells must retain
the ability to exit into the peripheral circulation providing
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Thymic emigration is mediated by the sphingosine-1-
phosphate receptor 1 (S1PR1), which is expressed on
thymocytes and responds to an S1P gradient (reviewed in
[99]), and while its expression has not been examined in
ALCL or in the mouse models, it is possible that the presence
of a transgenic TCR (as discussed below) might modulate its
expression. S1PR1 is a G-protein-coupled receptor whose
expression on SP CD4 or CD8 thymocytes is modulated by
the strength of signal induced via the TCR on ligation with
self-antigen presented in the context of MHC [99]. High-
avidity interactions lead to akt-induced phosphorylation of
FOXO1 preventing its activity as a transcription factor for
S1PR1, thereby, preventing thymic export [99]. Given that
NPM-ALK is able to mimic TCR proximal signalling, its co-
expression with a transgenic TCR may alter presumed avidity
for peptide-MHC and subsequent regulation of thymic
export. Indeed, in the absence of examining the thymi of
patients affected by ALCL, it was shown that backcrossing
CD4/NPM-ALK to TCR transgenic mice (OTI; MHC class I
restricted) led to PTCL development exactly mimicking the
human disease [86]. Whether the observed phenotype is
due to the combined effect of the transgenic TCR and
NPM-ALK in activating proximal TCR signalling remains to
be determined, but given the known role for TCR avidity
and subsequent strength of the transduced signal in mediating
thymic survival and emigration of T cells, this remains a dis-
tinct possibility. Furthermore, this peripheral phenotype was
only observed on a RAG-competent background, suggesting
that clonal competition with T cells expressing endogenously
rearranged TCR might be a contributing factor; only germline
endogenous TCR genes were present in tumours, suggesting
either suppression of RAG-induced endogenous rearrange-
ment in the presence of the TCR transgene or that T cells
with endogenously rearranged transgenes are inhibited from
tumour development [86]. Indeed, RAG-negative littermates,
which would only produce clonal TCR transgenic receptor
expressing T cells, did not develop lymphoid malignancy.
This is in contrast with a previous study whereby NPM-ALK
expression in transgenic TCR-expressing T cells only produced
tumours in the absence of clonal competition (i.e. in the
absence of polyclonal TCR-expressing T cells) [68].
These observations are in line with a study by Wang et al.,
in which snf5 was conditionally deleted by the cre-loxP
system with cre recombinase regulated by the CD2 promoter,
which is expressed before progenitor cells enter the thymus
[25]. In the CD2cre snf5fl/fl mouse, T-cell development was
blocked at the DN3 stage and no lymphoma developed, but
introduction of the OT1 TCR transgene into the CD2cre
snf5fl/fl mouse resulted in the presence of mature T cells in
the periphery and all mice developed CD3þCD8þ T-cell
lymphomas. As previously mentioned, there is evidence of
a DN3 block in the CD4/NPM-ALK mouse, suggesting simi-
lar mechanisms are at work in the CD2cre snf5fl/fl model of
lymphomagenesis and the CD4/NPM-ALK model. The
difference appears to be that NPM-ALK-expressing cells are
able to overcome the DN3 block, as seen in the CD4/NPM-
ALK/RAG2/2 line, whereas snf5 loss is unable to do the
same. However, the similarity is that the presence of
the OT1 TCR was able to radically alter the phenotype
of the model, and notably in neither study did the OT1
TCR need to be stimulated by ovalbumin administration to
achieve this result [25,86]. This suggests that TCR signallingat the thymocyte stage rather than activation in the periphery
is a crucial addition, perhaps simply as a way of over-
coming the DN3 block in a manner that enables survival
and emigration from the thymus.5.4. Anaplastic large-cell lymphoma development and
the role of the antigen receptor
As discussed above, the strength of signal transduced
through the TCR combined with its modulation by NPM-
ALK in the thymus might be critical for peripheral disease
development. But what is clear is that in the established
tumours, the TCR is often expressed in neither the NPM-
ALK/OTI mouse model nor in human tumours, which
would seem to preclude a role for antigen receptor signalling
in the periphery in the progression of the disease. Supporting
this supposition is the fact that ALCLs lack expression of TCR
molecules or molecules of proximal TCR signalling [96],
which might provide a selective advantage to the tumour
cells as loss of such proteins has been implicated in protection
from activation-induced cell death (AICD) in other lympho-
mas [100]. Despite this there are reasons to believe that TCR
signalling does play an oncogenic role in the pathogenesis
of ALCL: not only are TCRb chain rearrangements found in
the majority of cases, but more significantly the cells express
proteins associated with activated T cells (CD30, perforin and
Granzyme B) [70]. This suggests either that signalling via the
TCR happened at some point prior to downregulation (the
latter putatively via epigenetic mechanisms [101]), or alterna-
tively NPM-ALK induces aberrant expression of these
molecules. To support the latter point, it has been shown
that NPM-ALK induces expression of cytotoxic molecules
in ALCL [72]. However, it is also thought that a so-called
‘second hit’ of a foreign body triggering a strong immune
response is crucial to the pathogenesis of ALCL. Indeed,
there is a strong association of systemic ALK-positive ALCL
presenting with skin lesions occurring after an insect bite
[59]. The hypothesis is that the release of cytokines at the
site of the bite elicits the activation and proliferation of T
cells bearing the NPM-ALK translocation. As such, one
cannot preclude an innate lymphoid cell-type reaction of
the tumour cells to inflammation, independent of a TCR.
Regardless, complementary to investigating the potential
cell of origin, the role of TCR signalling in ALCL is pertinent
in order to determine the extent to which T-cell activation is
relevant to the generation of the disease either as an oncogene
or tumour suppressor that must be silenced.
Supporting the latter, exposure of the CD4/NPM-ALK/
OT1 mouse to MHV-OVA abrogated ALCL development in
favour of hepatocellular carcinomas and sarcoma, as seen
in the CD4/NPM-ALK/RAG2/2/OT1 mice [86]. This
demonstrates that cognate peripheral TCR signalling in
NPM-ALK-expressing cells is not compatible with ALCL
development and/or survival. Thus, coexistence with a func-
tional TCR allows thymic egress, but also subsequent cell
death in the presence of simultaneous TCR and NPM-ALK
signalling, by a process analogous to thymic negative selection.
As such, the TCR acts as a tumour suppressor, which must be
downregulated for development of classical, peripheral ALCL.
Indeed, it has been shown that epigenetic mechanisms are
induced by NPM-ALK to downregulate proteins of proximal
TCR signalling [101,102]. This goes some way to explain the
NPM-ALK
(Notch1)
b selection
DN
DP
pre-TCRa
TCRb TCRa
CD4 or CD8 SPMHC recognition
positive selection
NPM-ALK + TCR
signal strength?
no MHC recognition
death by neglect
high affinity TCR for self-
antigen: MHC
negative selection
bone marrow
precursor
Figure 3. Mechanisms of ALCL pathogenesis. The generation of the t(2;5), variant translocation or other oncogenic driver event occurs in a T-cell progenitor (blue
arrows) and is permissive of TCR VDJ recombination but also facilitates bypass of the beta selection checkpoint, enabling cells with TCR that would normally lead to
cell death to survive. These cells must then be positively selected, suggesting that either low-affinity TCR are expressed and/or that NPM-ALK mimics a TCR signal of
correct intensity permissive of survival. NPM-ALK-expressing T cells emigrate into the periphery and, dependent on the inflammatory microenvironment encountered
and bodily location, differentiate into distinct T-cell subsets potentially in a TCR-independent manner (akin to innate lymphoid cells) or following selection of cells
that have downregulated the TCR (or proteins involved in proximal TCR signalling). Owing to the acquisition of further (epi)genetic events, the transformed cells
clonally expand independently of the source of inflammation. DN, double negative; DP, double positive; SP, single positive.
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expressed TCR in ALCL.6. Conclusion
For most in the field, the consensus has been that B- and T-cell
lymphomas emerge in developmentally late-stage, differen-
tiated lymphocytes, with chronic antigen stimulation being a
key initiator and driver of disease. This is for good reason as
there are numerous examples to support this. However, it is
possible that the ‘seeds’ of these mature diseases are sown
much earlier in development, with predisposing genetic
events occurring in primitive cells and the final disease
phenotype shaped by activities occurring in the developing
differentiated cell. Notably for ALCL, a lymphoma that
would appear a prime candidate for an origin in an ‘activated’mature cytotoxic T cell, new evidence suggests that a thymic
origin is a possibility in a portion of the cases (figure 3). The
importance of this distinction is that while lymphomas are
generally defined by their appearance and location in the
periphery, effective treatment and relapse prevention requires
eradication of all pools of transformed cells. Thus, by showing
that progenitor lymphocytes can be the origin for T-cell lym-
phomas such as ALCL, we ensure that we can eliminate any
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